Sign In
Buy RCKT
$3.11
-0.100 (-3.12%)
At Close: Jul 31, 2026
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17
ATLANTA, July 28, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Rocket Pharmaceuticals, Inc. (“Rocket Pharmaceuticals” or the “Company”) (NASDAQ: RCKT). The lawsui
BENSALEM, Pa., July 28, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G.
NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (NASDAQ: RCKT)
NEW YORK , July 28, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT). Such inve
RCKT Investors Have Opportunity to Lead Rocket Pharmaceuticals, Inc. Securities Fraud Lawsuit
01:00pm, Saturday, 26'th Jul 2025
NEW YORK , July 26, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between February 27, 20
SAN DIEGO, July 26, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals,
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) between September 17
NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.
Rocket Refocuses Pipeline As Gene Therapy Sentiment Sours
03:02pm, Friday, 25'th Jul 2025
Rocket Pharmaceuticals, Inc. RCKT, a firm focused on developing cardiovascular gene therapy, announced a strategic corporate reorganization to extend its runway.
FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman
01:33pm, Friday, 25'th Jul 2025
SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an exp
LOS ANGELES, July 25, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming August 11, 2025 deadline to file a lead plaintiff motion in the class action filed on behal
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals
11:40am, Friday, 25'th Jul 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Opt
NEW YORK , July 25, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit. CLASS
